Zavegepant for acute migraine with CGRP preventives
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests how well a new acute migraine medicine, zavegepant, works and is tolerated in people who are already taking a CGRP-targeting preventive medication. It may help you find an effective treatment when you get a migraine attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with migraine (with or without aura) by a doctor.
- You are at least 18 years old.
- You have between 2 and 8 migraine attacks per month.
- You have been on a stable dose of a CGRP-targeting preventive medication (like atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, or rimegepant) for at least 2 months or two doses.
- You have no other primary headache disorders (mild tension headaches are fine).
- You have not had a serious allergic reaction to zavegepant or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new migraine medicines, rimegepant and zavegepant, given to people in the emergency department to see how well they work for stopping a migraine headache quickly.
This trial studies how well a “gepant” medicine works for different types of migraine and how tolerable it is. It may help if you have frequent migraines and you can keep a headache diary as the study asks.
This study tests a medicine called rimegepant to see if it helps prevent migraines. If you have migraine at least 4 days per month, this might be for you.
This trial tests whether a medication called rimegepant can prevent migraines when you take it before a known trigger (like exercise or stress). It is for people who get migraines often and can predict when one might happen.
This study tests if the drug rimegepant can help prevent migraine attacks in women. It aims to see how well it works in real life in China.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.